Wnt signaling as a regulator of memory T cells: implications for CAR-T cell therapy - Top-Institutions - MDSpire

Wnt signaling as a regulator of memory T cells: implications for CAR-T cell therapy

  • By

  • Tatiana Fourfouris

  • Ki Jun Lee

  • Samantha Hurwitz

  • Asher Ahdoot

  • Alexander Lee

  • Maiah Zarrabi

  • Michael Kahn

  • Yong-Mi Kim

  • May 13, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology-Oncology

  • #2

    University of Pennsylvania
    University of Pennsylvania

    Philadelphia, PA

    Key Differentiators

    • Hematology-Oncology

  • #3

    National Cancer Institute
    National Cancer Institute

    Bethesda, MD

    Key Differentiators

    • Hematology-Oncology

  • #4

    Roswell Park Comprehensive Cancer Center
    Roswell Park Comprehensive Cancer Center

    Buffalo, NY

    Key Differentiators

    • Hematology-Oncology

Original Source(s)

Wnt signaling as a regulator of memory T cells: implications for CAR-T cell therapy

  • by Tatiana Fourfouris, Ki Jun Lee, Samantha Hurwitz, Asher Ahdoot, Alexander Lee, Maiah Zarrabi, Michael Kahn, Yong-Mi Kim

  • May 13, 2026

Related Content

COA and Flatiron Health Study Finds Patients May Experience Longer Survival in Community Oncology Settings

Patients diagnosed with metastatic breast cancer and non–small cell lung cancer had longer survival compared to national benchmarks when treated in independent community oncology practices, according ...

Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants

Dietary patterns in young patients with lung cancer suggest that many have higher dietary quality scores than average U.S. reference values, according to results from a study presented at the American...

Unique Phase I NSCLC Trial Sites Decreasing in United States

The number of unique clinical trial sites in the United States with phase I studies for patients with non–small cell lung cancer (NSCLC) decreased by 44% from 2020 to 2024, showing a significant conso...